# CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus

> **NCT07659704** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Sao Paulo** · enrollment: 16 (estimated)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **BIOLOGICAL:** Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center

## Key facts

- **NCT ID:** NCT07659704
- **Lead sponsor:** University of Sao Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07659704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07659704, "CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07659704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*